KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Payables (2016 - 2025)

Historic Payables for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $23.1 million.

  • Neogenomics' Payables fell 8961.71% to $23.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.1 million, marking a year-over-year decrease of 8961.71%. This contributed to the annual value of $23.1 million for FY2025, which is 8961.71% down from last year.
  • As of Q4 2025, Neogenomics' Payables stood at $23.1 million, which was down 8961.71% from $22.6 million recorded in Q3 2025.
  • Neogenomics' 5-year Payables high stood at $222.4 million for Q4 2024, and its period low was $13.7 million during Q3 2022.
  • For the 5-year period, Neogenomics' Payables averaged around $60.2 million, with its median value being $21.6 million (2022).
  • As far as peak fluctuations go, Neogenomics' Payables soared by 118983.89% in 2024, and later plummeted by 8961.71% in 2025.
  • Over the past 5 years, Neogenomics' Payables (Quarter) stood at $17.9 million in 2021, then increased by 14.45% to $20.5 million in 2022, then fell by 0.86% to $20.3 million in 2023, then surged by 993.66% to $222.4 million in 2024, then plummeted by 89.62% to $23.1 million in 2025.
  • Its Payables was $23.1 million in Q4 2025, compared to $22.6 million in Q3 2025 and $27.5 million in Q2 2025.